{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang ZL"],"funding":["National Key Basic Research Program","National Natural Science Foundation of China","Natural Science Foundation of Jiangsu Province"],"pagination":["1700847"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5980201"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(5)"],"pubmed_abstract":["Oxygen (O2) plays a critical role during photodynamic therapy (PDT), however, hypoxia is quite common in most solid tumors, which limits the PDT efficacy and promotes the tumor aggression. Here, a safe and multifunctional oxygen-evolving nanoplatform is costructured to overcome this problem. It is composed of a prussian blue (PB) core and chlorin e6 (Ce6) anchored periodic mesoporous organosilica (PMO) shell (denoted as PB@PMO-Ce6). In the highly integrated nanoplatform, the PB with catalase-like activity can catalyze hydrogen peroxide to generate O2, and the Ce6 transform the O2 to generate more reactive oxygen species (ROS) upon laser irradiation for PDT. This PB@PMO-Ce6 nanoplatform presents well-defined core-shell structure, uniform diameter (105 ± 12 nm), and high biocompatibility. This study confirms that the PB@PMO-Ce6 nanoplatform can generate more ROS to enhance PDT than free Ce6 in cellular level (p < 0.001). In vivo, the singlet oxygen sensor green staining, tumor volume of tumor-bearing mice, and histopathological analysis demonstrate that this oxygen-evolving nanoplatform can elevate singlet oxygen to effectively inhibit tumor growth without obvious damage to major organs. The preliminary results from this study indicate the potential of biocompatible PB@PMO-Ce6 nanoplatform to elevate O2 and ROS for improving PDT efficacy."],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Oxygen-Evolving Mesoporous Organosilica Coated Prussian Blue Nanoplatform for Highly Efficient Photodynamic Therapy of Tumors."],"pmcid":["PMC5980201"],"funding_grant_id":["2014CB744504","81501538","81230032","81322020","BK20160017","2014CB744501","81530054"],"pubmed_authors":["Teng ZG","Zhang LJ","Zhao Y","Liu Y","Zhang YL","Wang Q","Tian W","Wang SJ","Tian Y","Tang YX","Lu GM","Ni QQ","Yang ZL"],"additional_accession":[]},"is_claimable":false,"name":"Oxygen-Evolving Mesoporous Organosilica Coated Prussian Blue Nanoplatform for Highly Efficient Photodynamic Therapy of Tumors.","description":"Oxygen (O2) plays a critical role during photodynamic therapy (PDT), however, hypoxia is quite common in most solid tumors, which limits the PDT efficacy and promotes the tumor aggression. Here, a safe and multifunctional oxygen-evolving nanoplatform is costructured to overcome this problem. It is composed of a prussian blue (PB) core and chlorin e6 (Ce6) anchored periodic mesoporous organosilica (PMO) shell (denoted as PB@PMO-Ce6). In the highly integrated nanoplatform, the PB with catalase-like activity can catalyze hydrogen peroxide to generate O2, and the Ce6 transform the O2 to generate more reactive oxygen species (ROS) upon laser irradiation for PDT. This PB@PMO-Ce6 nanoplatform presents well-defined core-shell structure, uniform diameter (105 ± 12 nm), and high biocompatibility. This study confirms that the PB@PMO-Ce6 nanoplatform can generate more ROS to enhance PDT than free Ce6 in cellular level (p < 0.001). In vivo, the singlet oxygen sensor green staining, tumor volume of tumor-bearing mice, and histopathological analysis demonstrate that this oxygen-evolving nanoplatform can elevate singlet oxygen to effectively inhibit tumor growth without obvious damage to major organs. The preliminary results from this study indicate the potential of biocompatible PB@PMO-Ce6 nanoplatform to elevate O2 and ROS for improving PDT efficacy.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 May","modification":"2025-04-26T08:29:34.78Z","creation":"2019-03-26T23:40:35Z"},"accession":"S-EPMC5980201","cross_references":{"pubmed":["29876209"],"doi":["10.1002/advs.201700847"]}}